SCHEMBL34051

SCHEMBL34051

O[C@@H](CCCCCS)C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 6/20 0.43
HDAC1 Q13547 9/20 0.39
HDAC4 P56524 8/20 0.39
HDAC3 O15379 8/20 0.39
HDAC2 Q92769 8/20 0.39
HDAC10 Q969S8 8/20 0.39
HDAC11 Q96DB2 8/20 0.39
HDAC8 Q9BY41 8/20 0.39
HDAC6 Q9UBN7 8/20 0.39
HDAC7 Q8WUI4 7/20 0.39
HDAC9 Q9UKV0 7/20 0.39
HDAC5 Q9UQL6 7/20 0.39
MEN1 O00255 1/20 0.34
TTR P02766 1/20 0.34
KMT2A Q03164 1/20 0.34
ALDH1A1 P00352 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34050 1.00 FOLH1 (0.43) FOLH1HDAC1HDAC4HDAC3HDAC2
SCHEMBL10770500 0.85 MEN1 (0.38) FOLH1MEN1TTRKMT2AALDH1A1
SCHEMBL11290864 0.84 KDM4E (0.33) MEN1TTRKMT2ACYP2C19
SCHEMBL9011486 0.79 FOLH1 (0.40) FOLH1HDAC1HDAC4HDAC3HDAC2
SCHEMBL17396368 0.77 CPA3 (0.39) FOLH1CYP2C19
SCHEMBL17913818 0.76 FOLH1 (0.49) FOLH1HDAC1HDAC4HDAC3HDAC2
SCHEMBL1160457 0.76 FOLH1 (0.49) FOLH1HDAC1HDAC4HDAC3HDAC2
SCHEMBL8659893 0.75 TRPA1 (0.37) MEN1TTRKMT2AALDH1A1CYP2D6
SCHEMBL8053148 0.74 KCNN4 (0.33) HDAC2HDAC6ALDH1A1
SCHEMBL8086291 0.73 KIF11 (0.34) MEN1TTRKMT2AALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127797-A1 PRODRUG COMPRISING A DRUG-LINKER CONJUGATE ASCENDIS PHARMA A/S (DK) 2025-04-24 US disclosed
US-20240041897-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA GMBH (DE) 2024-02-08 US disclosed
US-20220331334-A1 Prodrug Comprising a Drug-Linker Conjugate ASCENDIS PHARMA A/S (DK) 2022-10-20 US disclosed
EP-3981761-A2 INTERMEDIATES FOR PRODRUGS Ascendis Pharma A/S (DK) 2022-04-13 EP disclosed
EP-2596805-B1 Prodrug comprising a drug-linker conjugate ASCENDIS PHARMA AS (DK) 2021-10-27 EP disclosed
US-20200046725-A1 Prodrug Comprising a Drug Linker Conjugate ASCENDIS PHARMA A/S (DK) 2020-02-13 US disclosed
EP-2237799-B1 PRODRUG COMPRISING A SELF-CLEAVABLE LINKER ASCENDIS PHARMA AS (DK) 2019-04-10 EP disclosed
US-20170100490-A1 Prodrug Comprising a Drug Linker Conjugate ASCENDIS PHARMA A/S (DK) 2017-04-13 US disclosed
US-20150057221-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA AS (DK) 2015-02-26 US disclosed
US-8906847-B2 Prodrug comprising a drug linker conjugate ASCENDIS PHARMA A/S (DK) 2014-12-09 US disclosed
EP-2596805-A1 Prodrug comprising a drug linker conjugate Ascendis Pharma A/S (DK) 2013-05-29 EP disclosed
US-20110053848-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA AS (DK) 2011-03-03 US disclosed
EP-2237799-A2 PRODRUG COMPRISING A SELF-CLEAVABLE LINKER Ascendis Pharma AS (DK) 2010-10-13 EP disclosed
WO-2009095479-A2 PRODRUG COMPRISING A SELF-CLEAVABLE LINKER ASCENDIS PHARMA AS (DK) 2009-08-06 WO disclosed
EP-0202758-B1 HYBRIDIZATION METHOD AND PROBES THEREFOR Zeneca Limited (GB) 1991-09-25 EP disclosed
EP-0202758-A1 Hybridization method and probes therefor ZENECA LIMITED (GB) 1986-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150057221-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE H1-0, H1-3, H1-2 FOLH1 651/4885HDAC1 437/4885HDAC4 1085/4885
US-20170100490-A1 Prodrug Comprising a Drug Linker Conjugate H1-0, H1-3, H1-2 FOLH1 651/4885HDAC1 437/4885HDAC4 1085/4885
US-20110053848-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE H1-0, H1-3, H1-2 FOLH1 642/4885HDAC1 439/4885HDAC4 1070/4885
US-20200046725-A1 Prodrug Comprising a Drug Linker Conjugate H1-0, H1-3, H1-2 FOLH1 643/4885HDAC1 439/4885HDAC4 1065/4885
US-20240041897-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE H1-0, H1-3, H1-2 FOLH1 651/4885HDAC1 437/4885HDAC4 1085/4885
US-20220331334-A1 Prodrug Comprising a Drug-Linker Conjugate H1-0, H1-3, DLST FOLH1 620/4885HDAC1 561/4885HDAC4 1239/4885
US-20250127797-A1 PRODRUG COMPRISING A DRUG-LINKER CONJUGATE H1-0, H1-3, DLST FOLH1 620/4885HDAC1 561/4885HDAC4 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.